Nirogacestat

Unassigned

New Medicines

Desmoid tumour or aggressive fibromatosis (fibroma)

Information

New molecular entity
SpringWorks Therapeutics
SpringWorks Therapeutics

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Selective, small molecule, gamma-secretase inhibitor
Desmoid tumours account for <3% of soft tissue tumours. Annual incidence is estimated to range between 1/250,000-1/500,000. They predominantly affect women and can occur between the ages of 15-60 years, but frequently during early adolescence and with a peak age of about 30 years [3].
Desmoid tumour or aggressive fibromatosis (fibroma)
Oral